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Abstract
Purpose: To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular
signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-
naive patients with unresectable stage III/IV melanoma.
Experimental Design: This phase II, open-label,multicenter, randomized, parallel-group study examined
the effect of 100mg oral selumetinib twice daily in 28-day cycles versus oral temozolomide (200mg/m2/d for
5 days, then 23 days off-treatment). The primary endpoint was progression-free survival.
Results: Two hundred patients were randomized. Progression-free survival did not differ significantly
between selumetinib and temozolomide (median time to event 78 and 80 days, respectively; hazard ratio,
1.07; 80%confidence interval, 0.86–1.32).Objective responsewas observed in six (5.8%) patients receiving
selumetinib and nine (9.4%) patients in the temozolomide group. Among patients with BRAFmutations,
objective responses were similar between selumetinib and temozolomide groups (11.1% and 10.7%,
respectively). However, five of the six selumetinib partial responders were BRAF mutated. Frequently
reported adverse events with selumetinib were dermatitis acneiform (papular pustular rash; 59.6%),
diarrhea (56.6%), nausea (50.5%), and peripheral edema (40.4%), whereas nausea (64.2%), constipation
(47.4%), and vomiting (44.2%) were reported with temozolomide.
Conclusions: No significant difference in progression-free survival was observed between patients with
unresectable stage III/IV melanoma unselected for BRAF/NRAS mutations, who received therapy with
selumetinib or temozolomide. Five of six patients with partial response to selumetinib had BRAF mutant
tumors. Clin Cancer Res; 18(2); 555–67. 2011 AACR.
Introduction
The Ras/Raf/MEK/ERK pathway is a key signaling cascade
driving cell-cycle proliferation, differentiation, and survival
(1, 2). Mutations affecting signaling molecules, including
Ras and Raf, activate this pathway and contribute to malig-
nant progression in many human cancers (3–6). BRAF and
NRAS mutations are generally mutually exclusive in mela-
noma (7, 8). At the time of study initiation, the mutation
frequencies for BRAF andNRAS were estimated as 59% (9)
and 30% (10), respectively. However, recent estimates
suggest that the frequency for BRAF mutations may be as
low as 41% (11).
Agents targeting mutated BRAF are in development (12,
13); however, they may be associated with paradoxical
activation of the mitogen-activated protein (MAP) kinase
pathway in BRAF wild-type cells (14). MAP/extracellular
signal-regulated (ERK) kinase (MEK) 1/2 is an attractive
therapeutic target due to its key positionwithin the Ras/Raf/
MEK/ERK pathway (2, 15) and paradoxical activation
effects are not expected with MEK inhibitors. Selumetinib
(AZD6244/ARRY-142886) is an orally available, potent,
selective, allosteric inhibitor of MEK1/2 with preclinical
antitumor activity in melanoma (16), which has been
shown to inhibit the growth of cell lines expressing BRAF
V600E mutation (17, 18).
In a phase I trial of selumetinib including patients with
melanoma (20 of 57 patients, 35%), prolonged stable
disease (SD)of 5 ormoremonthswasobserved in 9patients
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(16%; ref. 19). Themaximum tolerated dose of selumetinib
was determined as 200 mg twice a day; however, the dose
chosen for ongoing phase II studies was 100mg twice a day
due to the frequency of treatment-related rash with chronic
administration. Consistent inhibition of ERK phosphory-
lation shown between pre- and posttreatment biopsies
showed that this dose results in target inhibition. This study
also showed that selumetinib 100 mg twice a day was
considered to have a manageable toxicity profile.
The current study compared the efficacy of orally admin-
istered selumetinib and temozolomide in patients with
chemotherapy-naive advanced melanoma. It is the first
multicenter randomized study conducted in patients with
melanoma assessed for both BRAF andNRASmutations. At
the time of initiation, there was no global standard of care
for patientswith chemotherapy-naive advancedmelanoma;
therefore, temozolomide was chosen as comparator for
this study because it had been used in both clinical
trials and was licensed for this indication in some countries
(20). In addition, temozolomidehas the sameactivemetab-
olite [5-(3-methyl-1-triazeno)imidazole-4-carboxamide] as
dacarbazine, an approved treatment for advanced melano-
ma, but temozolomide has the benefit of being adminis-
tered orally. The dose of temozolomide (200mg/m2/d for 5
days, followed by 23 days off-treatment) used in the present
study is the recommended monotherapy dose (21) which
was used in a large phase III study in patients with advanced
melanoma (22).
Material and Methods
This phase II, open-label, multicenter, randomized,
parallel-group study (clinicaltrials.gov registry number
NCT00338130) enrolled patients without previous sys-
temic chemotherapy for advanced melanoma between
July 2006 and June 2007 and was conducted in accor-
dance with good clinical practice guidelines and the
Declaration of Helsinki. Thirty-four centers from 10
countries participated in this trial: Argentina (3 centers),
Australia (3), Austria (2), Brazil (6), Canada (2), Den-
mark (1), France (3), Switzerland (1), the United King-
dom (3), and United States (10).
Patient selection
All included patients provided written informed consent
and fulfilled the following criteria: age18 years, histologic
or cytologic confirmation of unresectable American Joint
Committee on Cancer (AJCC) stage III or IV malignant
melanoma, at least one measurable site of disease defined
by Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.0, World Health Organization (WHO) perfor-
mance status 0–2, and willingness to provide tumor biopsy
(fresh or archival) for determination of BRAF and NRAS
mutation status. Female patients were required to have a
negative pregnancy test or be postmenopausal. To be rep-
resentative of the general melanoma population, the num-
ber of patients with uveal melanoma was limited to 20 of
the planned 182.
Exclusion criteria included absolute neutrophil count
<1,500/mm3, platelets <100,000/mm3, hemoglobin 9
g/dL, serum creatinine clearance 30 mL/min, serum bil-
irubin 1.5  upper limit of normal (ULN), aspartate
aminotransferase 2.5  ULN, alanine aminotransferase
2.5  ULN, or serum creatinine 1.5 mg/dL, chemother-
apy or radiotherapy within 5 years prior to start of study
treatment (excluding palliative radiotherapy at focal sites),
any systemic chemotherapy for unresectable AJCC stage III
or IV melanoma, prior combination biochemotherapy for
cancer, unstable brain metastasis or spinal cord compres-
sion (<3 months off steroids), and history of another
primary malignancy within 5 years prior to start of study
treatment (except for adequately treated basal or squamous
cell skin cancer or cancer of the cervix in situ).
Study design
Patients were randomized 1:1 to selumetinib (100 mg
free-base solution, twice daily in 28-day cycles) or temozo-
lomide (200 mg/m2/d for 5 days, followed by 23 days off
treatment). Assessment by RECIST criteria was conducted at
weeks 6 and 12 and then every 8 weeks for progression-free
survival (PFS). Local center tumor assessment was used for
the primary analysis, with conclusions validated by an
independent central review of scans/images. Patients could
continue study treatment until objective disease progres-
sion (defined by local investigator) and were then followed
for survival. Patients with progressive disease (PD), as
assessed by the investigator in the temozolomide group,
were permitted to crossover to selumetinib.
Data cutoff point was September 28, 2007, for PFS and
objective tumor response. All other analyses, including
time-to-death (TTD) used a date of June 20, 2008.
Translational Relevance
The Ras/Raf/MEK/ERK pathway is a key signaling
cascade driving cell-cycle proliferation, differentiation,
and survival. Activations in this pathway contribute to
malignant progression in many human cancers. Selu-
metinib (AZD6244/ARRY-142886) is an oral inhibitor
ofmitogen-activated protein (MAP)/extracellular signal-
regulated (ERK) kinase (MEK1/2) currently in clinical
development for a number of tumor types. Preclinical
studies have shown antitumor activity of selumetinib in
melanoma xenograft models particularly those harbor-
ing BRAF mutations. In this study, there was no signif-
icant difference in efficacy between selumetinib and
temozolomide as first-line therapy for patients with
advanced melanoma not selected for activating BRAF
mutations. Of note, 5 of the 6 patients showing partial
response with selumetinib had tumors that were BRAF
mutant. On the basis of these results, and preclinical
data, a phase II study of selumetinib in combination
with chemotherapy for patients with BRAF-mutated
melanoma has been initiated.
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Study objectives
The primary objective was to compare the efficacy of
selumetinib versus temozolomide in patients with unre-
sectable stage III or IV malignant melanoma. The primary
outcomewas PFS. Secondary outcomes were TTD, objective
response rate (ORR), and duration of response.
PFS, defined as the interval between the date of random-
ization and the first date of objective disease progression
(RECIST 1.0) or death due to any cause, was to be analyzed
following approximately 126 progression events. Nonpro-
gressing patients were censored at last objective tumor
assessment.
TTD was calculated from randomization until death due
to any cause; surviving patients were censored at last date
known to be alive, or withdrawal of consent.
Best objective response [OR; complete response (CR),
partial response (PR), SD6weeks] or PDwas calculated as
the best response, using RECIST 1.0, recorded from date of
randomization.
Secondary objectives included assessment of safety, tol-
erability, and efficacy of selumetinib versus temozolomide
with respect to BRAF or NRAS mutation status.
Exploratory analyses included assessment of the treat-
ment effect in the following subgroups; disease stage (stage
III vs. stage IV), uvealmelanoma versus non-uveal, mucosal
melanoma versus non-mucosal, andBRAF andNRASmuta-
tion status.
Assessment of safety
Adverse events, serious AEs (SAE), clinical laboratory
evaluations, vital signs, and electrocardiograms were col-
lected from provision of informed consent until 30 days
after discontinuation of study treatment. Adverse events
were collected using Common Terminology Criteria for
Adverse Events (CTCAE) version 3.
Determination of BRAF and NRAS mutation status
Pathology review confirmed the presence of tumor; no
enrichment by macrodissection was conducted prior
to DNA extraction, given the high sensitivity of the
allele-specific PCR-based method ARMS (Amplification
Refractory Mutation System). The methods used for
mutation detection including sequences of primers and
probes for detection of BRAF and NRAS mutations
have been previously described (23). The allele-specific
PCR detects BRAF V600E as well as V600K and V600D
(1799T>A) and the allele-specific PCR for NRAS
detects NRAS Q61K mutation (C181A) and the Q61R
mutation (A182G). Mutation testing was carried out
centrally within the AstraZeneca Tumor Genetics
Research Laboratory.
In brief, genomic DNA was extracted from thin sections
totaling 40 mm by digestion in proteinase K for 48 hours,
boiling in 5% chelex, phase-extracting in chloroform, eth-
anol-precipitating, and resuspending in 100 mL water. PCR
was carried out as described previously, using cell line
admixtures containing the mutation of interests to act as
positive controls (23).
A mutation-positive result was only accepted if it was
present in two independent PCRs generated from the same
DNA sample. Normal genomic DNAwas used as a negative
control. Results were not designated positive unless the
mutation was detected at a level above the nonspecific
background noise. This was done to control for false-pos-
itive results. A "negative" result from an assay could repre-
sent no mutation present; if there was insufficient DNA
extracted from the sample to identify the presence of the
mutation, it was designated a fail.
Determination of GNAQ mutation status
GNAQ analysis was conducted in uveal melanoma
tumors only. Codon 209 was analyzed by ARMS and direct
sequencing. The same forward primer was used for both
sequencing and ARMS: 50-ACTGTAAAACGACGGCCAGTT-
TTTCCCTAAGTTTGTAAGTAGTGCT-30. Reverse primers
were used as follows:GNAQ sequencing reverse, 50-ACCAG-
GAAACAGCTATGACCGTCTGACTCCACGAGAACTTGAT-
30; GNAQ 209P ARMS reverse, 50-AGTGTATCCATTZTCT-
TCTCTCTGACCTTP-30; GNAQ 209L ARMS reverse, 50-
AGTGTATCCATTZTCTTCTCTCTGACCTTE-30 [L ¼ LNA
(locked nucleic acid) modified C, P ¼ LNA G, Z ¼ LNA T].
Statistical and analytic methods
A sample size of 182patients (91per arm)was required to
provide adequate power for comparison of PFS between the
two treatment groups both in the overall population and in
the BRAF mutant subpopulation (24). Patients with BRAF
mutant tumors (assumed to be 60%of the total; ref. 9) were
hypothesized to show a greater response to selumetinib
than those with wild-type tumors. The target PFS HR in the
BRAFmutant subgroup was 0.67 (and was to be tested as a
secondary endpoint at the one-sided significance level of
20%).
To maintain statistical power for the overall population,
the target HR on which the study was powered was 0.74 for
PFS (i.e., a 35% delay in median time to progression
assuming exponential distribution). This assumed that the
BRAF wild-type subpopulation contained NRAS mutant
patients (30%), who might derive clinical benefit.
This study was designed to have 80% power to detect a
true PFS HR of 0.74 in the overall population at the one-
sided 20% significance level and required approximately
126 progression events. The trial was designed as a ran-
domized screening trial to quantify the level of risk entailed
for further development, and as such, the type I and type II
errors were adjusted to be less constrained, so that the
targeted treatment benefit may be appropriate, whereas the
sample size remains reasonable (as discussed by Rubinstein
and colleagues; ref. 25).
PFS and TTD were analyzed using a Cox proportional
hazards model allowing for the effect of treatment and
fitting for the following baseline covariates: BRAFmutation
status (positive vs. negative vs. unknown), WHO perfor-
mance status (0 vs. 1 or 2), tumor type [non-uveal (cuta-
neous, mucosal, unknown) vs. uveal], and level of lactate
dehydrogenase (<2ULNvs.2ULN) at baseline. These
Selumetinib versus Temozolomide in Patients with Advanced Melanoma
www.aacrjournals.org Clin Cancer Res; 18(2) January 15, 2012 557
covariates were thought to be potentially prognostic, and
thus the impact of these covariates is adjusted for in the
statistical analyses to improve the precision of the estimated
treatment effect as well as compensating for any lack of
balance between groups for these baseline covariates. The
model included these effects regardless of whether the
inclusion of effects significantly improved the fit of the
model. These analyses were prespecified in the Statistical
Analysis Plan. Tumor stage (III vs. IV) was prespecified as a
covariate but not included in the model as only 6 patients
had an unresectable AJCC stage III tumor.
Intention-to-treat (ITT) analysis was used for all efficacy
analyses. The ITT population included all randomized
patients and compared the treatment groups on the basis
of randomized treatment, regardless of the treatment actu-
ally received. The evaluable-for-safety population was a
subset of the ITT population that included all patients who
received 1 dose of study treatment and was used for
summaries of the safety data.
Results
Demographics and other patient characteristics
Two hundred thirty-nine patients were enrolled, of whom
200 were randomized: 104 to selumetinib and 96 to temo-
zolomide (Fig. 1). Of these patients, 99 and 95 received
selumetinib and temozolomide, respectively. Ninety-six and
92 patients, respectively, discontinued assigned treatment
with selumetinib or temozolomide. Three patients in each
arm were continuing assigned treatment at the time of
data cutoff. Fifty-nine patients in the temozolomide arm
switched to selumetinib. In total, 158 randomized patients
(79.0%) had their BRAF and NRAS mutation status con-
firmed. BRAF mutant tumors were identified in 73 of 158
patients (46.2%; V600E, 66; V600K, 5; K601E, 1; K581S, 1);
28 of 158 patients’ tumors (17.7%) were NRAS mutated
(Q61K, 15; Q61R, 12; G13R, 1). No tumors were both BRAF
and NRAS mutated; therefore, 101 of 158 patients’ tumors
(63.9%) were either BRAF mutant or NRAS mutant. Of the
42 patients without confirmed mutation status, 24 did not
have samples to analyze and 18 had no result due to assay
failure.
The study population was representative of the advanced
melanoma clinical population in terms of baseline and
demographic characteristics; however, there were some
imbalances between the treatment arms (Table 1). There
was a higher percentage of women in the selumetinib group
(47.1%) than in the temozolomide group (32.3%). In
addition, more patients were BRAF mutant in the selume-
tinib group (43.3%) than in the temozolomide group
(29.2%), and more patients in the selumetinib group had
WHO performance status 1 or 2 than those receiving temo-
zolomide (33.7% and 26.1%, respectively).
In the BRAF and NRAS mutant subpopulation, more
patients had WHO performance status 1 or 2 in the selume-
tinib group (38.2%) than in the temozolomide group
(23.9%). Furthermore,more BRAF orNRASmutant patients
in the selumetinib group (12.7%)had lactate dehydrogenase
levels 2  ULN than those in the temozolomide group
(8.7%). The analyses adjusted for these factors.
Twenty (10%) patients in the study had uvealmelanoma,
with 15 evaluable for BRAF/NRASmutations; nomutations
in BRAF or NRAS were detected. Twelve patients with uveal
melanoma had tumors with sufficient material evaluable
for GNAQ mutation: 4 tumors were GNAQ mutated
(3 GNAQ 209P, 1 GNAQ 209L), 8 tumors were GNAQ
wild-type.
Efficacy
Progression-free survival based on investigator-assessed
RECIST data. The PFS analysis was conducted after
151 progression events. No difference in PFS was
observed between selumetinib and temozolomide [HR,
1.07; 80% confidence interval (CI), 0.86–1.32; 1-sided P
¼ 0.650; 2-sided P ¼ 0.699; Fig. 2A). In prespecified
analyses, PFS was consistent across subgroups (data not
shown) except for patients with uveal melanoma (HR,
0.70; 80% CI, 0.35–1.42) but no significant difference
could be concluded for patients with uveal melanoma
due to the small number of patients (16 events/20
patients) and wide CI. Overall, 79 (76%) patients in the
selumetinib group and 72 (75%) patients randomized to
temozolomide had objective disease progression or had
died at the data cutoff point, with median time to event of
78 and 80 days, respectively.
Because of open-label nature of the study, an indepen-
dent central review was incorporated to assess consistency
and ensure that conclusions were robust. Discordance
between the disease status assessment in local and central
review was noted, with local review more favorable for
selumetinib (Supplementary Table S1; ref. 26). In 20% of
cases, the discrepancy was due to different assessments of
percentage change of target lesions alone and 31%were due
to the identification of one or more new lesions alone
(Supplementary Table S2) either by the local review or by
central review. This discordance did not change the con-
clusions of this study.
Time to death. The final analysis of TTD was conducted
after 130 deaths had occurred. The median TTD was 284
and 369 days for selumetinib and temozolomide groups,
respectively (HR, 1.351; 80% CI, 1.07–1.71; 95% CI, 0.95–
1.93; 1-sided P ¼ 0.950; 2-sided P ¼ 0.099; Table 2),
suggesting improved but not statistically significant TTD
for temozolomide compared with selumetinib in the over-
all population (Fig. 2B). A higher proportion of patients
randomized to temozolomide received selumetinib follow-
ing disease progression (61%) compared with those who
received temozolomide or dacarbazine following progres-
sion on selumetinib (24%). The frequency of crossover
from selumetinib to temozolomide may be an underesti-
mation as this informationwas notmandatorily gathered as
part of the study protocol.
Objective response rate based on investigator-assessed
RECIST data. Statistical comparisons of ORR and dura-
tionof responsewerenot formally conducted because of the
low number of responses. The number of patients with
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confirmed PR was 5.8% (6 of 104) for patients in the
selumetinib group and 9.4% (9 of 96) in the temozolomide
group (Table 3). No CRs were observed in either group.
Forty-eight (46.2%) patients in the selumetinib group had
SD of6weeks’ duration compared with 36 (37.5%) in the
temozolomide group. At the time of the overall survival
analysis, two new PRs were observed in patients with wild-
type tumors randomized to temozolomide and one temo-
zolomide patientwith a previous PRbecame aCR.Of the 11
responders in the temozolomide group, the duration of
response ranged from 94 to420 days (3 patients were still
responding at timeof data cutoff). In the selumetinib group,
the duration of response ranged from 130 to 358 days (all
patients had progressed).
Number of patients enrolled
N = 239
Number of patients randomized
n = 200
Selumetinib
n = 104
Temozolomide
n = 96
Received selumetinib
n = 99
Received temozolomide
n = 95
Ongoing on initial 
study treatment (n = 3)
Ongoing on initial 
study treatment (n = 3)
Not randomized (n = 39) because of:
• Incorrect enrollment (n = 27)
• Voluntary discontinuation (n = 7)
• Other (n = 3)
• Safety reasons (n = 1)
• Subject lost to follow-up (n = 1)
Patients (n = 5) did not 
receive treatment due to:
• Incorrect enrollment (n = 2)
• Unknown (n = 2)
• Other (n = 1)
One patient did not 
receive treatment due 
to incorrect enrollment
Discontinued initial treatment (n = 92) due to:
• Disease progression (n = 81)
• Adverse event (n = 2)
• Othera (n = 9)
Discontinued initial treatment (n = 96)
because of:
• Disease progression (n = 78)
• Adverse event (n = 10)
• Othera (n = 3)
• Patient not willing to continue study 
  treatment (n = 5)
Switched to selumetinib (n = 59):
• Objective disease progression (n = 54)
• Incorrect switching (n = 5)
Figure 1. Patient disposition.
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Efficacy in patients with BRAF or NRASmutations. There
were no significant differences in PFS between the two
treatment groups in the BRAF mutant (Fig. 2C) and BRAF
orNRASmutant subsets (not shown). Among patients with
BRAF mutation, objective tumor response was observed in
11.1% (5 of 45) of patients receiving selumetinib and
10.7% (3 of 28) of the temozolomide group. Similarly, in
the patient subpopulation with BRAF or NRAS mutations,
the objective tumor responseswere 9.1%(5of 55) and8.7%
(4 of 46) in the selumetinib and temozolomide groups,
respectively (Table 3). Of the 6 selumetinib responders, 5
were BRAFmutant compared with 3 of the 9 temozolomide
responders. As with the overall population, BRAF mutant
patients randomized to temozolomide had improved TTD
compared with those randomized to selumetinib (Fig. 2D).
Efficacy in patients who switched treatment. As of Sep-
tember 28, 2007, 51 patients randomized initially to temo-
zolomide had switched to selumetinib; 46 (90.2%)
switched following objective disease progression and 5
patients switched incorrectly (before objective disease
Table 1. Patient demographics and baseline characteristics
Treatment group, n (%)
Selumetinib
(n ¼ 104)
Temozolomide
(n ¼ 96)
Sex
Male 55 (52.9) 65 (67.7)
Female 49 (47.1) 31 (32.3)
Age, y
Mean (range) 57.1 (20–84) 57.0 (28–84)
Racial origin
Caucasian 99 (95.2) 91 (94.8)
Non-Caucasiana 3 (2.9) 3 (3.0)
Unknown 2 (1.9) 2 (2.1)
WHO performance status
0 Normal activity 67 (64.4) 71 (74.0)
1 restricted activity 34 (32.7) 23 (24.0)
2 in-bed  50% of the time 1 (1.0) 2 (2.1)
Unknown 2 (1.9) 0 (0)
AJCC staging
Stage III 3 (2.9) 3 (3.1)
Stage IV 99 (95.2) 92 (95.8)
M1a/b 40 (38.5) 36 (37.5)
M1c 58 (55.8) 54 (56.3)
Unknown M status 1 (1) 2 (2.1)
Unknown stage 2 (1.9) 1 (1.0)
Lactate dehydrogenase level at baseline
<2  ULN 79 (76.0) 79 (82.3)
2  ULN 17 (16.3) 15 (15.6)
Unknown 8 (7.7) 2 (2.1)
Tumor type
Cutaneous 75 (72.1) 72 (75.0)
Uveal 7 (6.7) 13 (13.5)
Mucosal 6 (5.8) 0 (0.0)
Unknown primary tumor 16 (15.4) 11 (11.5)
Mutation status
BRAF positive 45 (43.3) 28 (29.2)
NRAS positive 10 (9.6) 18 (18.8)
Wild-type for both 29 (27.9) 28 (29.2)
Unknownb 20 (19.2) 22 (22.9)
aThis group comprised Black, Hispanic, and Mediterranean patients.
bThisgroupcomprised thosepatientswhere therewasno result for bothBRAFandNRASmutation statusor oneof themutation assays
failed.
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progression as assessed by site RECIST data). Three switches
were due to an incorrect assessment of objective disease
progression and the other two resulted from clinical pro-
gression alone (the latter two patients went on to progress
according to RECIST 28 and 64 days after switching to
AZD6244; the first patient had new lesions and the second
died).
As of June 20, 2008, 59 of the 96 patients randomized to
temozolomide (61%) had switched to selumetinib (54 of
59 patients after objective disease progression). No further
patients had incorrectly switched prior to disease progres-
sion. One patient (2%) had PR, 25 (46%) had PD, and 8
(15%) were not evaluable. Two patients who switched
exhibited PR while receiving selumetinib; however, one of
these switched prior to objective disease progression on
temozolomide and so is counted as a response to temozo-
lomide. The patient with confirmed PR on selumetinib
following progression to temozolomide was BRAFmutant.
Change in tumor size. Exploratory plots were produced
to assess the change from baseline in tumor size by week
6 and best overall change at time of primary analysis
(Supplementary Fig. S1). Overall, there was little difference
Figure 2. Comparison of PFS (A)
and (C) and of TTD (B) and (D)
between selumetinib and
temozolomide in the overall
population (A) and (C) and BRAF
mutant patients (B) and (D).
A, Kaplan–Meier comparison of PFS
between selumetinib and
temozolomide in the overall
population (ITT population). B,
Kaplan–Meier comparison of TTD
between selumetinib and
temozolomide in the overall
population (ITT population).
100
90
80
70
60
50
40
30
20
10
0
0 30 60 90 120 150 180 210 240 270
Number at risk:
  
Selumetinib  104 92 52 36 29 13 9 3 2 1
  
Temozolomide    96 86 48 32 29 12 9 4 3 3
Time to progression (d)
Pr
o
gr
es
si
on
 fr
ee
 (x
)
Temozolomide
Selumetinib
Censored observation = X
A
B
HR = 1.07; 80% CI, 0.86–1.32
x
x x
x
x x
x x
x
x
x
x
x
xx
xxxx x x xxxx xx
x
xx
xxxx
x
100
90
80
70
60
50
40
30
20
10
0
0 60 120 180 240 300 360 420 480 540
Number at risk:
  
Selumetinib  104 90 73 67 56 47 38 21 11 2
  
Temozolomide    96 90 82 68 60 52 45 24 17 3
Time to death (d)
A
liv
e 
(x)
Temozolomide
Selumetinib
Censored observation = X
HR = 1.351; 80% CI, 1.07–1.71
Selumetinib versus Temozolomide in Patients with Advanced Melanoma
www.aacrjournals.org Clin Cancer Res; 18(2) January 15, 2012 561
between the two treatment groups for change in tumor size,
either at week 6 or for best overall change.
Safety
Adverse events. Most adverse events reported in this
study were CTCAE grade I or II and were manageable with
drug holiday or standard supportive therapy (Table 4).
Fewer patients in the temozolomide group had treat-
ment-related adverse events, adverse events  grade III,
SAEs or adverse events leading to discontinuation com-
pared with the selumetinib group. The most frequent SAEs
in the selumetinib group were diarrhea (n ¼ 3), vomiting
(n¼ 3), and infections (n¼ 3). Small intestinal obstruction
(n¼2) and confusional state (n¼2)were themost frequent
SAEs in the temozolomide group. Three deaths were
reported in patients receiving selumetinib; one death
due to unknown cause occurred in the absence of tumor
progression, one patient died of metastases to meninges
(disease progression), and one patient experienced cardio-
respiratory arrest that was attributed to selumetinib by the
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Figure 2. (Continued) C, Kaplan–
Meier comparison of PFS between
selumetinib and temozolomide in
the BRAF mutant subpopulation
(ITT population). D, Kaplan–Meier
comparison of TTD between
selumetinib and temozolomide in
the BRAF mutant subpopulation
(ITT population).
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investigator. A further selumetinib-randomized patient
died outside of the 30-day follow-up reporting period as
a result of myocarditis.
The most commonly reported adverse events were der-
matitis acneiform (59.6%), diarrhea (56.6%), and nausea
(50.5%) in the selumetinib group, and nausea (64.2%),
constipation (47.4%), and vomiting (44.2%) in the temo-
zolomide group (Table 4).
Laboratory evaluation. Deterioration in hematology
parameters of at least two grades from baseline was
observed in fewer patients treated with selumetinib than
with temozolomide; leukocytes (1.0% vs. 8.5%), lympho-
cytes (6.1% vs. 14%), neutrophils (2.0% vs. 7.5%), and
platelets (1.0% vs. 11.7%).
A greater proportion of patients receiving selumetinib
showed deterioration of at least two grades from baseline in
clinical chemistry parameters than with temozolomide:
alanine aminotransferase (13.1% vs. 3.2%), aspartate
aminotransferase (11.8% vs. 2.4%), and albumin (16.3%
vs. 1.1%). Bilirubin levels remained normal in both treat-
ment groups.
A slight increase in calcium phosphate product level
was observed in the selumetinib group, with 6 patients
reporting levels above the predefined cutoff value (4.5
mmol/L). One of these patients had an SAE (grade III) of
hyperphosphatemia.
Small increases in mean systolic (7.4 mm Hg) and dia-
stolic (5.3 mm Hg) blood pressure, without a correspond-
ing change in heart rate, were observed in the selumetinib
group by week 8. Hypertension was reported as an adverse
event by 8 (8.1%) patients in the selumetinib group and 2
(2.1%) in the temozolomide group.
Discussion
Advanced melanoma represents one of the most treat-
ment-refractory malignancies. Despite decades of research,
worldwide consensus on a standard first-line treatment has
yet to be established.While dacarbazine and temozolomide
are used for first-line chemotherapy of advanced melano-
ma, patient response to these agents is low (22, 27). The
present study investigated the role of the oral MEK1/2
inhibitor selumetinib as monotherapy for patients with
unresectable stage III/IV melanoma. No significant differ-
ence was seen in the primary endpoint of PFS between the 2
treatment arms for either the overall population or the
subpopulations of patients with BRAF or BRAF/NRAS
mutant tumors. Although some imbalances were seen
between treatment groups in baseline covariates, the statis-
tical analyses adjusted for the impact of these factors.
Disease control (5.8% PR; 46.2% SD) with selumetinib
monotherapy was observed. Because of the open-label
nature of this trial, an independent central review of tumor
assessment was incorporated to ensure consistency. How-
ever, as stated in the protocol, the primary efficacy analysis
was based on the investigator-assessed RECIST data, as this
was considered to be more reflective of clinical practice and
the central review was not carried out in real-time. As has
been reported for other studies (28), differences between
local and central reviewwere noted but this did not alter the
conclusions of the primary analyses.
Tumor responses to selumetinibmonotherapy have been
observed in patients with melanoma and other solid
tumors, suggesting antitumor activity with this MEK1/2
inhibitor. Cell lines expressing BRAF or RAS mutations
Table 2. Summary of TTD analysis for selumetinib versus temozolomide in the overall population and in
BRAF and NRAS mutant patients
Number
of patients
Number
of deaths (%)
Median time
to event (d)
HRa CI P
Two-sided,
80%
Two-sided,
95%
One-sidedb Two-sided
Overall populationc
Selumetinib 104 73 (70.2) 284 1.351 1.07, 1.71 0.95, 1.93 0.950 0.099
Temozolomide 96 57 (59.4) 369
BRAF mutant subpopulationd
Selumetinib 45 34 (75.6) 284 1.654 1.12, 2.45 0.91, 3.02 0.949 0.102
Temozolomide 28 16 (57.1) 369
BRAF and NRAS mutant subpopulationd
Selumetinib 55 42 (76.4) 275 1.621 1.18, 2.23 0.99, 2.65 0.973 0.053
Temozolomide 46 27 (58.7) 383
aHR < 1 indicated a beneﬁt for selumetinib.
bThe one-sided P indicated whether selumetinib was associated with longer TTD than temozolomide.
cAnalyzed using Cox proportional hazards model, adjusted for lactate dehydrogenase, BRAF mutational status, WHO performance
status, and primary tumor type.
dAnalyzed using the Cox proportional hazards model, adjusted for lactate dehydrogenase and WHO performance status.
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(including melanoma cell lines) have increased sensitivity
to selumetinib (29). This is particularly relevant to mela-
noma as recent estimates suggest that activating mutations
of BRAF and NRAS are found in 41% and 18% of melano-
mas, respectively (11). Although the present study did not
test for mutation status prospectively, 79% of patients had
mutation status confirmed retrospectively. Retrospective
mutation testing could be considered a limitation of this
study, given the imbalance seen between treatment arms.
However, the rationale for prespecified retrospective testing
was 2-fold: first, implementing prospective testing of
patients would require central testing in a time frame that
might withhold treatment from patients for a prolonged
period of time, and second, the primary objective was to
assess efficacy in the overall population, and so making
patients wait for a mutation test before starting treatment,
when the result would not exclude them from entering the
trial, was felt not to be in the patients’ best interests.
The observed BRAFmutation rate of 46.2% is lower than
had been expected when planning this study but similar to
recent reports (11, 30, 31). Of note in our study, 5 of the 6
patients showing PRwith selumetinib had tumors that were
BRAF mutant. This finding raises the possibility that BRAF
mutation may be an important, but not exclusive, require-
ment for response to selumetinib. Data from other com-
pounds in development have shown that patients with
BRAFmutant tumors can show a high response rate to MEK
or BRAF inhibition (12, 13, 32–34). For example, a phase I
trial of the MEK inhibitor GSK112012 showed disease
control in 8 of 11 patients with BRAF mutant melanoma
(32). This suggests that additional genetic markers may be
necessary for a cell to respond to selumetinibmonotherapy.
In line with this hypothesis, a transcriptional profile asso-
ciated with activation ofMEK and sensitivity to selumetinib
preclinically has recently been identified, although thismay
not be predictive of clinical benefit (35). Testing conducted
on samples from this study showed no correlation between
this transcription profile and clinical response (AstraZe-
neca, data on file).
The clinical challenge is, therefore, to find ways of opti-
mizing the efficacy of selumetinib, for example, through
combination with other targeted agents or chemotherapy.
In preclinical models, selumetinib in combination with
docetaxel, irinotecan, gemcitabine, or temozolomide was
shown to have enhanced antitumor efficacy compared with
single-agent treatment (36). Preliminary clinical results
from a phase I trial of selumetinib in combination with
dacarbazine, docetaxel, or temsirolimus have shown
objective response in 5 of 9 patients with BRAF muta-
tion–positive tumors (37). Selumetinib is currently being
Table 3. Objective tumor response for selumetinib and temozolomide
Response status Objective tumor
response
Treatment group, n (%)
Selumetinib Temozolomide
Overall population n ¼ 104 n ¼ 96
Responsea CR 0 0
PR 6 (5.8) 9 (9.4)
Total 6 (5.8) 9 (9.4)
Nonresponse SD  6 wk 48 (46.2) 36 (37.5)
PD 40 (38.5) 43 (44.8)
Nonevaluable 10 (9.6) 8 (8.3)
Total 98 (94.2) 87 (90.6)
BRAF mutant subpopulation n ¼ 45 n ¼ 28
Responsea CR 0 0
PR 5 (11.1) 3 (10.7)
Total 5 (11.1) 3 (10.7)
Nonresponse SD  6 wk 18 (40.0) 12 (42.9)
PD 17 (37.8) 11 (39.3)
Nonevaluable 5 (11.1) 2 (7.1)
Total 40 (88.9) 25 (89.3)
BRAF and NRAS mutant subpopulation n ¼ 55 n ¼ 46
Responsea CR 0 0
PR 5 (9.1) 4 (8.7)
Total 5 (9.1) 4 (8.7)
Nonresponse SD  6 wk 23 (41.8) 21 (45.7)
PD 21 (38.2) 19 (41.3)
Nonevaluable 6 (10.9) 2 (4.3)
Total 50 (90.9) 42 (91.3)
aAn objective response included patients with either a conﬁrmed CR or PR according to RECIST version 1.0.
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investigated for advanced melanoma in combination with
dacarbazine for patients with prospectively determined
BRAF mutant tumors (NCT00936221).
Possible theories for the nonsignificant improved surviv-
al of patients initially assigned to temozolomide versus
selumetinib (other than a chance finding) were examined
but no clear explanation was found. First, selumetinib
might have had a detrimental effect in relation to survival,
but no differences in other efficacy endpoints (PFS, ORR,
change in tumor size) and safety data did not suggest this,
either in this trial or a separate comparative phase II trial
measuring TTD (38). Second, an imbalance in prognostic
factors might have contributed to this outcome, but this is
unlikely as imbalances in a range of prognostic factors
(lactate dehydrogenase, WHO performance status, BRAF
mutation status, and tumor type) had already been
accounted for in the TTD analysis. Third, an imbalance in
the number of patients that crossed over from temozolo-
mide to selumetinib, or vice versa (61% temozolomide arm
vs. 25% selumetinib arm), could have affected the out-
come; for example, the possibility that the sequential
administration of two equally active agents prolonged
survival (selumetinib has activity that is preliminarily in
the range of temozolomide and PFS curves are not dissim-
ilar). However, the relative activity of these agents in the
first- and second-line setting is unknown. In addition, the
relative activity of non-study treatments that non-crossover
patients went on to receive after temozolomide and selu-
metinib is unknown.
To be representative of the general melanoma popula-
tion, patients with uveal melanoma were included in this
study. It was felt that these patients have the potential to
benefit fromMEK inhibition because theymay carry somat-
ic mutations such as GNAQ and GNA11 (39). Analysis of
efficacy in these patients was an exploratory endpoint that
did not translate into a significant clinical benefit in this
trial. However, on the basis of anecdotal evidence from this
and a phase I study (19), a phase II study of selumetinib in
patients with uveal melanoma has been initiated,
NCT01143402.
Selumetinib was generally well tolerated; the reported
adverse events were consistent with prior reports (19, 40),
and no new clinically significant safety issues were identi-
fied in the present study. There was a higher reported
incidence of dermatitis acneiform, diarrhea, and peripheral
and periorbital edema with selumetinib than with temo-
zolomide. Nausea, vomiting, constipation, dyspnea, and
fatigue were more commonly reported in the temozolo-
mide group than in the selumetinib group, which is con-
sistent with the prescribing information for temozolomide.
Hematologic toxicities were not an issue with selumetinib.
Dermatologic toxicities with selumetinib resemble those
observed with epidermal growth factor receptor inhibitors
(41) in their clinical presentation (dermatitis acneiform,
xerosis cutis, paronychia; ref. 40). These skin toxicities can
be ameliorated by topical corticosteroid and/or antibacte-
rial therapy (40, 42) and responded to dose interruptions or
discontinuation of therapy. In the present study, selumeti-
nib-associated dermatologic conditions were manageable;
only one patient discontinued study treatment due to
dermatitis acneiform. It has been suggested that there may
be a link between rash and the signal transduction pathway.
An exploratory (unplanned) analysis of rash (maximum
grade on treatment) and efficacy (maximum change in
tumor size) found no relationship (AstraZeneca, data on
file).
Table 4. Most frequent all-causality adverse events (occurring in at least 15% of patients in each group),
SAEs, and discontinuations due to any adverse events
Number (%) of patients
Selumetinib (n ¼ 99) Temozolomide (n ¼ 95)
Preferred term AE AE  grade III AE AE  grade III
AE 99 (100.0) 57 (57.6) 92 (96.8) 36 (37.9)
Dermatitis acneiform 59 (59.6) 12 (12.1) 3 (3.2) 0 (0.0)
Diarrhea 56 (56.6) 4 (4.0) 20 (21.1) 0 (0.0)
Nausea 50 (50.5) 3 (3.0) 61 (64.2) 3 (3.2)
Peripheral edema 40 (40.4) 1 (1.0) 6 (6.3) 3 (3.2)
Fatigue 29 (29.3) 3 (3.0) 40 (42.1) 4 (4.2)
Vomiting 28 (28.3) 1 (1.0) 42 (44.2) 6 (6.3)
Headache 21 (21.2) 3 (3.0) 23 (24.2) 2 (2.1)
Pyrexia 16 (16.2) 1 (1.0) 10 (10.5) 0 (0.0)
Constipation 12 (12.1) 0 (0.0) 45 (47.4) 1 (1.1)
SAEs 32 (32.3) 16 (16.8)
Discontinuations due to AEs 10 (10.1) 2 (2.1)
NOTE: This table includes adverse eventswith anonset date between thedate of the ﬁrst dose and30days following thedate of the last
dose of study treatment (unless the patient switched to selumetinib earlier than 30 days following discontinuation of temozolomide).
Abbreviation: AE, adverse event.
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The toxicity profile of selumetinib in this trial therefore
appears to be manageable. However, it is possible that the
acceptable tolerability of selumetinibmaybe a consequence
of underdosing in this study and could, therefore, explain
the low number of responses observed. During develop-
ment of selumetinib, the dose-limiting toxicities and max-
imum tolerated dose were based on the frequency of rash. It
is possible that in the subsequent development of newer
MEK inhibitors, lessons were learnt from these early trials of
selumetinib and other MEK inhibitors, and the manage-
ment of rash that results from administration of this type of
drug is nowmore effective. For example, in a phase I trial of
the MEK inhibitor GSK1120212 which had disease control
rate of 73%, the frequency of rash was 77% (43). However,
the frequency of grade III rash was lower than that seen in
our study, suggesting that although the incidence of rash
may be higher overall, it could be better controlled with
optimal supportive care. It is therefore possible that thedose
of selumetinib used in this phase II study was overcautious
with regard to toxicity and that the maximal dosage range
was not explored in full. It should therefore be noted that
ongoing and future trials of selumetinib will use a 75-mg
hydrazine sulfate tablet formulation which shows statisti-
cally significantly higher plasma exposure as well as oral
bioavailability 197% that of the 100-mg free-base suspen-
sion used in this study (44).
In conclusion, the oral MEK1/2 inhibitor selumetinib
showed modest activity with no significant difference in
PFS compared with temozolomide in patients with chemo-
therapy-naive advanced melanoma unselected for BRAF
mutations. The objective tumor responses observed were
comparable in both the overall andBRAF andNRASmutant
populations; however, 5 of 6 selumetinib responders had
BRAFmutant tumors. Further development of selumetinib
in this disease will therefore focus on combination with
other agents and upon the selection of patients for therapy,
using BRAF mutation status.
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